TherapeuticsMD, Inc. TXMD
Set alert
1.80 USD -0.03 -1.64%
At close · Oct 30
1.80 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
1.80 Day range 1.82
1.15 52-week range 2.77
- YTD
- +10.43%
- 1 year
- +45.16%
- Open
- 1.80
- Prev close
- 1.83
- Mkt cap
- 20.83M
- Vol
- 3.83K
- Avg vol
- 23.74K
- EPS
- -0.04
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.80
- High
- 1.82
- Forward P/E
- 3.13
- Beta
- 0.00
- Short ratio
- 0.95
- Inst. own
- 44.53%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.42
- 200-d avg
- 1.79
- 1y target
- 0.00
Key statistics
- Market cap
- 12.63M
- Enterprise value
- 13.53M
- Trailing P/E
- 0.00
- Forward P/E
- 3.13
- PEG ratio
- 0.00
- Price / sales
- 7.91
- Price / book
- 0.47
- EPS (TTM)
- -0.35
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -207.77%
- Revenue (TTM)
- 1.60M
- Revenue growth
- 0.00%
- Free cash flow
- -8.38M
- Total cash
- 5.05M
- Total debt
- 5.78M
- Return on equity
- -14.39%
- Shares outstanding
- 11.53M
- Short % of float
- 0.25%
- 50-day average
- 1.42
- 200-day average
- 1.79
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
TXMD Revenue — quarterly 869.00K
TXMD Net income — quarterly 155.00K
TXMD EPS — quarterly 0.01
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | 0.00 | -0.05 | — | — |
| Aug 12, 2024 | Jun 1, 2024 | 0.00 | -0.09 | — | — |
| May 10, 2024 | Mar 1, 2024 | 0.00 | -0.07 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -0.13 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -0.24 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 17, 2023 | Cantor Fitzgerald | reit | Neutral | Neutral |
| Jul 13, 2022 | Cantor Fitzgerald | reit | — | Neutral |
| Jun 7, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- therapeuticsmd.com
News
- TherapeuticsMD (NASDAQ:TXMD) and Tilray Brands (NASDAQ:TLRY) Financial Review
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- TherapeuticsMD Q2 EPS $0.01 Down From $0.05 YoY, Sales $869.000K Down From $952.000K YoY
- TherapeuticsMD Announces Second Quarter 2026 Financial Results
- TherapeuticsMD Announces Second Quarter 2026 Financial Results
- 12 Health Care Stocks Moving In Friday's Intraday Session
- TherapeuticsMD Announces First Quarter 2026 Financial Results
- TherapeuticsMD Announces Full Year 2025 Financial Results
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- TherapeuticsMD Announces Third Quarter 2025 Financial Results
Your note
Sign in to keep a note on TXMD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COLLINS COOPER C | Director | Purchase | Aug 21, 2024 | 52,016 |
| DONEGAN MICHAEL C | Chief Financial Officer | Conversion of Exercise of derivative security | Apr 11, 2023 | 61,853 |
| RUBRIC CAPITAL MANAGEMENT L.P. | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Nov 14, 2023 | 0 |
| WALKER MARLAN D | Chief Executive Officer | Sale | Dec 6, 2023 | 62,565 |
| ZIEGLER JOSEPH | Chief Financial Officer | Stock Award(Grant) | Aug 16, 2023 | 7,500 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Rubric Capital Management LP | 10.34% | 1,192,191 | 1.31M | Sep 29, 2024 |
| Clearline Capital, LP | 5.52% | 636,622 | 697.10K | Sep 29, 2024 |
| Tejara Capital Ltd | 3.48% | 401,446 | 439.58K | Sep 29, 2024 |
| Vanguard Group Inc | 3.36% | 387,582 | 424.40K | Sep 29, 2024 |
| Adar1 Capital Management, LLC | 2.34% | 270,160 | 295.82K | Sep 29, 2024 |
| Morgan Stanley | 1.14% | 131,719 | 144.23K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.16% | 249,657 | 273.37K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.06% | 122,234 | 133.85K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.56% | 64,619 | 70.76K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.29% | 34,000 | 37.23K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.13% | 15,320 | 16.77K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.13% | 14,835 | 16.24K | Oct 30, 2024 |